Ambit Biosciences Corp just filed a General Statement of acquisition of beneficial ownership


The following excerpt is from the company's filing:

Item 5.Interest in Securities of the Issuer.

As of May 21, 2013, after giving effect to the IPO and the Private Placement, Forward Ventures IV, L.P. was the beneficial and record owner of 950,876 shares of Common Stock, Forward Ventures IV B, L.P. was the beneficial and record owner of 80,608 shares of Common Stock and Forward Ventures IV-C, L.P. was the beneficial and record owner of 6,735 shares of Common Stock (such 1,038,219 shares of Common Stock to be referred to collectively as the Record Shares).By virtue of the affiliate relationship between Forward Ventures IV, L.P., Forward Ventures IV B, L.P. and Forward Ventures IV-C, L.P., each entity may be deemed to beneficially own all of the Record Shares.As the sole general partner of both Forward Ventures IV, L.P. and Forward Ventures IV B, L.P., Forward IV Associates, LLC may be deemed to beneficially own the Record Shares.As the sole general partner of Forward Ventures IV-C, L.P., Forward IV-C Associates, LLC may be deemed to beneficially own the Record Shares.As the managing members of each of Forward IV Associates, LLC and Forward IV-C Associates, LLC, each of Standish M. Fleming and Ivor Royston, M.D. may be deemed to beneficially own the Record Shares. As a key member of Forward IV Associates, LLC, Stuart Collinson, Ph.D. may be deemed to beneficially own the Record Shares.
Each Reporting Person expressly disclaims beneficial ownership of any shares of Common Stock of the Issuer, except in the case of (1) Forward Ventures IV, L.P. for the 950,876 shares of Common Stock it holds of record; (2) Forward Ventures IV B, L.P. for the 80,608 shares of Common Stock it holds of record; and (3) Forward Ventures IV-C, L.P. for the 6,735 shares of Common Stock it holds of record.
(a)
Percent of Class:Each Reporting Person 5.9%.The foregoing percentage is calculated based on the 17,712,558 shares of Common Stock reported to be outstanding in the Issuers Prospectus filed with the Securities and Exchange Commission on May 15, 2013.
(b)
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote:See line 7 of the cover sheets.
(ii)
Shared power to vote or to direct the vote:See line 8 of the cover sheets.
(iii)
Sole power to dispose or to direct the disposition:See line 9 of the cover sheets.
(iv)
Shared power to dispose or to direct the disposition:See line 10 of the cover sheets.
(c)
None of the Reporting Persons has effected any transaction in the Common Stock of the Issuer during the last 60 days.
(d)
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of the shares beneficially owned by any of the Reporting Persons.
(e)
Not Applicable.

CUSIP NO. 02318X100
13D Page 13 of17 Pages
Item 6.
Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Ambit Biosciences Corp makes a similar move, sign up!

Other recent filings from the company include the following:

Ambit Biosciences Corp just filed a General Statement of acquisition of beneficial ownership - Oct. 24, 2014
Solicitation, recommendation statements - Oct. 10, 2014
Tender offer statement by Third Party - Oct. 10, 2014
Written communication relating to an issuer or third party - Sept. 30, 2014
Written communication relating to an issuer or third party - Sept. 29, 2014

   Auto Refresh

Feedback